51 research outputs found
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
There is a remarkable heterogeneity in the functional profile (quality) of T cell responses. Importantly, the magnitude and/or quality of a response required for protection may be different depending on the infection. Here, we assessed the capacity of different Toll like receptor (TLR)-binding compounds to influence T helper cell (Th)1 and CD8+ T cell responses when used as adjuvants in nonhuman primates (NHP) with HIV Gag as a model antigen. NHP were immunized with HIV Gag protein emulsified in Montanide ISA 51, an oil-based adjuvant, with or without a TLR7/8 agonist, a TLR8 agonist, or the TLR9 ligand cytosine phosphate guanosine oligodeoxynucleotides (CpG ODN), and boosted 12 wk later with a replication-defective adenovirus-expressing HIV-Gag (rAD-Gag). Animals vaccinated with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist had higher frequencies of Th1 responses after primary immunization compared to all other vaccine groups. Although the rAD-Gag boost did not elevate the frequency of Th1 memory cytokine responses, there was a striking increase in HIV Gag-specific CD8+ T cell responses after the boost in all animals that had received a primary immunization with any of the TLR adjuvants. Importantly, the presence and type of TLR adjuvant used during primary immunization conferred stability and dramatically influenced the magnitude and quality of the Th1 and CD8+ T cell responses after the rAD-Gag boost. These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses
Economic analysis including long-term risks and costs of alternative diagnostic strategies to evaluate patients with chest pain
Background: Diagnosis costs for cardiovascular disease waste a large amount of healthcare
resources. The aim of the study is to evaluate the clinical and economic outcomes of alternative
diagnostic strategies in low risk chest pain patients.
Methods: We evaluated direct and indirect downstream costs of 6 strategies: coronary
angiography (CA) after positive troponin I or T (cTn-I or cTnT) (strategy 1); after positive exercise
electrocardiography (ex-ECG) (strategy 2); after positive exercise echocardiography (ex-Echo)
(strategy 3); after positive pharmacologic stress echocardiography (PhSE) (strategy 4); after positive
myocardial exercise stress single-photon emission computed tomography with technetium Tc 99m
sestamibi (ex-SPECT-Tc) (strategy 5) and direct CA (strategy 6).
Results: The predictive accuracy in correctly identifying the patients was 83,1% for cTn-I, 87% for
cTn-T, 85,1% for ex-ECG, 93,4% for ex-Echo, 98,5% for PhSE, 89,4% for ex-SPECT-Tc and 18,7%
for CA. The cost per patient correctly identified results 2.086 for cTn-T, 803 for ex-Echo, 1.521 for ex-SPECT-Tc (29.673 for CA ($29.999 including cost of extra risk of cancer). The
average relative cost-effectiveness of cardiac imaging compared with the PhSE equal to 1 (as a cost
comparator), the relative cost of ex-Echo is 1.5×, of a ex-SPECT-Tc is 3.1×, of a ex-ECG is 3.5×,
of cTnI is ×3.8, of cTnT is ×3.9 and of a CA is 56.3×.
Conclusion: Stress echocardiography based strategies are cost-effective versus alternative
imaging strategies and the risk and cost of radiation exposure is void
Innate immunity against HIV: a priority target for HIV prevention research
This review summarizes recent advances and current gaps in understanding of innate immunity to human immunodeficiency virus (HIV) infection, and identifies key scientific priorities to enable application of this knowledge to the development of novel prevention strategies (vaccines and microbicides). It builds on productive discussion and new data arising out of a workshop on innate immunity against HIV held at the European Commission in Brussels, together with recent observations from the literature
Effects of pravastatin treatment on vitamin D metabolites
Hyperlipidemias, and notably hypercholesterolemia, represent important risk factors for atherosclerotic vascular disease. The enzymatic inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a selective and specific key enzyme involved in endogenous cholesterol synthesis, cause a significant mean reduction in low-density lipoprotein (LDL) cholesterol, both in familial and nonfamilial hypercholesterolemic forms. It has been hypothesized that these compounds might interfere with vitamin D endogenous synthesis secondarily to their effects on cholesterol. To verify this hypothesis, we studied 14 hypercholesterolemic patients treated as follows: 4 weeks of low-lipid, fiber-rich diet followed by 8 weeks of pravastatin treatment at the oral evening dose of 20 mg/d and by a 1-month washout period. No significant changes in serum calcium, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D were noticed; on the contrary, significant (P < 0.01) reductions in total cholesterol and LDL cholesterol and a significant (P < 0.05) increase in high-density lipoprotein cholesterol were observed. After the final 1-month washout period, all values returned to baseline levels. In conclusion, our study confirms the clinical efficacy of pravastatin on lipid fractions and demonstrates the absence of any interference on the circulating levels of the main vitamin D metabolite
- …